Loading
companiesCompany
Xcovery
Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first.
Also called: Xcovery Holdings, Inc.
Overview
Xcovery Holdings, based in Palm Beach Gardens, Florida, developed ensartinib (Ensacove), a second-generation ALK inhibitor. Its Chinese partner Betta Pharmaceuticals won approval there in 2020, and the FDA approved ensartinib in December 2024 for ALK-positive locally advanced or metastatic non-small-cell lung cancer in patients not previously treated with an ALK inhibitor, on the eXalt3 trial against crizotinib. Company facts are from the official website and FDA approval records.
Headquarters
Palm Beach Gardens, FL, US
Scorecard
All companies#234of 1244 companies, score 22
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 1 targets, 27 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedSmall-molecule ALK TKI (second generation)
Ensartinib · Ensacove
A Chinese-developed ALK pill approved in the US in December 2024 for first-line ALK-positive lung cancer.
Similar pages
- CompanyMerck KGaA (EMD Serono)
Shares Non-small-cell lung cancer and the tag fda-oce-applicant.
- PersonHeather A. Wakelee
Shares eXalt3, Non-small-cell lung cancer.
- PersonMartin Reck
Shares eXalt3, Non-small-cell lung cancer.
- PersonTony S. K. Mok
Shares eXalt3, Non-small-cell lung cancer.
- TrialALTA-1L
Shares eXalt3, Non-small-cell lung cancer.
- TrialCROWN
Shares eXalt3, Non-small-cell lung cancer.
- TrialALEX
Shares eXalt3, Non-small-cell lung cancer.
- BiomarkerALK fusion (ALK-positive)
Shares Ensartinib, Non-small-cell lung cancer.